ADVANCES IN Cancer IMMUNOTHERAPY™

Immunotherapy of Hematologic Malignancies

Edmund K. Waller, MD, PhD, FACP

Winship Cancer Institute Emory University

Association of Community Cancer Centers

Society for Immunotherapy of Cancer

ADVANCES IN Cancer IMMUNOTHERAPY™

Disclosures

- Consulting fees from Novartis, Kalytera, Shionogi, and Amgen.
- Stock owenership in Chimerix and Cerus.
- Co-founder and equity hold of Cambium Medical Technologies.
- I will be discussing non-FDA approved indications during my presentation.

ACCC Association of Community Cancer Centers

sitc Society for Immunotherapy of Cancer

ADVANCES IN Cancer IMMUNOTHERAPY™

Immunological Modalities to Treat Cancer



ACCC Association of Community Cancer Centers

sitc Society for Immunotherapy of Cancer

ADVANCES IN Cancer IMMUNOTHERAPY™

Monoclonal antibodies targeting B cell lymphomas



ADVANCES IN Cancer IMMUNOTHERAPY™

Monoclonal antibodies targeting T cell lymphomas



ADVANCES IN Cancer IMMUNOTHERAPY™

Checkpoint inhibitors

- Reed-Sternberg cells express both PD-L1 and PD-L2
- Expression of ligands increases with advanced disease
- Unclear whether PD-L1/L2 expression correlates with response to treatment







Ansell SM et al. N Engl J Med 2015;372:311-319

ADVANCES IN Cancer IMMUNOTHERAPY™



FDA-approved checkpoint inhibitors for hematologic malignancies

- Nivolumab (anti-PD-1)
  - CheckMate – 205/039: Patients with cHL that has relapsed or progressed after autologous hematopoietic stem cell transplantation and posttransplantation brentuximab vedotin
  - Accelerated approval – May 17th, 2016

- Pembrolizumab (anti-PD-1)
  - KEYNOTE – 087: Adult and pediatric patients with refractory cHL, or patients whose disease has relapsed after three or more lines of therapy
  - Accelerated approval – March 14th, 2017

ADVANCES IN Cancer IMMUNOTHERAPY™



Nivolumab in Hodgkin lymphoma

Table 3. Clinical Activity in Nivolumab-Treated Patients.*

Variable	All Patients (N=23)	Failure of Both Stem-Cell Transplantation and Brentuximab (N=15)	No Stem-Cell Transplantation and Failure of Brentuximab (N=3)	No Brentuximab Treatment (N=5)†
Best overall response — no. (%)				
Complete response	4 (17)	1 (7)	0	3 (60)
Partial response	16 (70)	12 (80)	3 (100)	1 (20)
Stable disease	3 (13)	2 (13)	0	1 (20)
Progressive disease	0	0	0	0
Objective response				
No. of patients	20	13	3	4
Percent of patients (95% CI)	87 (66–97)	87 (60–98)	100 (29–100)	80 (28–99)
Progression-free survival at 24 wk — % (95% CI)‡	86 (62–95)	85 (52–96)	NC§	80 (20–97)
Overall survival — wk				
Median	NR	NR	NR	NR
Range at data cutoff¶	21–75	21–75	32–55	30–50

* NC denotes not calculated, and NR not reached.
† In this group, two patients had undergone autologous stem-cell transplantation and three had not.
‡ Point estimates were derived from Kaplan–Meier analyses; 95% confidence intervals were derived from Greenwood's formula.
§ The estimate was not calculated when the percentage of data censoring was above 25%.
¶ Responses were ongoing in 11 patients.

Ansell SM et al. N Engl J Med 2015;372:311-319

ADVANCES IN Cancer IMMUNOTHERAPY™



Nivolumab in Hodgkin lymphoma



Ansell SM et al. N Engl J Med 2015;372:311-319

ADVANCES IN Cancer IMMUNOTHERAPY™

Patient selection criteria for checkpoint inhibitor therapies

- Expression of the ligand for checkpoint inhibition
  - e.g. PD-L1 expression for anti-PD-1 therapy
- Relapse or progression after previous therapies
  - Nivolumab: After prior HSCT and brentuximab therapy
  - Pembrolizumab: Relapse after three prior treatments
- Presence of co-morbidities:
  - e.g. Presence of active autoimmune diseases which could be worsened

B cell malignancies are CD19+



Blanc, V et al., Clinical Cancer Research, Volume 17 , Issue 20

BiTE (blinatumumab) therapy

- Combines anti-CD19 F(ab) with anti-CD3 F(ab)
- Lacks the Fc region
- TOWER: Patients with relapsed/refractory B-cell precursor ALL
  - Regular approval: July 11th, 2017



BiTE therapy in ALL





Topp, Max S et al., The Lancet Oncology , Volume 16 , Issue 1 , 57 - 66

BiTE therapy in ALL



Topp, Max S et al., The Lancet Oncology , Volume 16 , Issue 1 , 57 - 66

Three Different Mechanisms of Cellular Immunotherapy



Brody J, et al. *J Clin Oncol.* 2011;29(14):1864-1875.

Chimeric Antigen Receptor (CAR) T Cell Therapy

Signal 1→ activation (CD3ζ)
Signal 2→ co-stimulation

2nd gen→ 4-1BB or CD28
3rd gen→ 4-1BB + CD28



Jackson HJ, et al. *Nat Rev Clin Oncol.* 2016;13(6):370-383.

ADVANCES IN Cancer IMMUNOTHERAPY™

Chimeric Antigen Receptor (CAR) T cell therapy

- Gene transfer technology stably expresses CARs on T cells[1,2]
- CAR T cell therapy takes advantage of the cytotoxic potential of T cells, killing tumor cells in an *antigen-dependent* manner[1,3]
- Persistent CAR T cells consist of both effector (cytotoxic) and central memory T cells[3]
- **T cells are *non-cross resistant* to chemotherapy**



1. Milone MC, et al. *Mol Ther.* 2009;17:1453-1464.
2. Hollyman D, et al. *J Immunother.* 2009;32:169-180.
3. Kalos M, et al. *Sci Transl Med.* 2011;3:95ra73.

ADVANCES IN Cancer IMMUNOTHERAPY™

CAR T cell therapy





ACCC Association of Community Cancer Centers

sitc Society for Immunotherapy of Cancer

FDA-approved CAR T cell therapies for hematologic malignancies

- Kymriah (tisagenlecleucel)
  - Patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse
  - Accelerated approval – August 30th, 2017

- Yescarta (axicabtagene ciloleucel)
  - ZUMA-1: Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma
  - Accelerated approval – October 18th, 2017

CAR T cell therapy in ALL





Maude SL et al. N Engl J Med 2014;371:1507-1517.

ADVANCES IN Cancer IMMUNOTHERAPY™

CAR T cell therapy in DLBCL

JULIET multi-institutional study

Response Rate	Patients (N = 51)[a]	
Best overall response (CR + PR)	59%	P < .0001[b] (95% CI, 44-72)
CR[1]	43%	
PR[1]	16%	
SD[1]	12%	
PD[1]	24%	
Overall response rate (CR + PR) at 3 months	45%	
CR[1]	37%	
PR[1]	8%	

CI, confidence interval; CR, complete remission; ORR, overall remission rate; PD, progressive disease; PR, partial remission; SD, stable disease.

Complete regression of DLBCL three months following CART therapy



CAR T cell therapy in DLBCL

JULIET multi-institutional study



- All responses at 3 months were ongoing at the time of cut-off
  - No responding patients went on to SCT
- Median DOR and OS not reached

ADVANCES IN Cancer IMMUNOTHERAPY™

CAR T cell therapy in DLBCL

Agent efficacy and safety

	CTL019[1]	KTE-C19[2,3]		JCAR017[4,5]
Disease state	r/r DLBCL	r/r DLBCL	r/r TFL/PMBCL	r/r DLBCL, NOS, tDLBCL, FL3B
Pts treated, n	85	77	24	28
Follow-up, median	NR	8.7 mo		NR
Efficacy				
ORR (best response)	59%	82%	83%	80%[a]
CR (best response)	**43%**	**54%**	**71%**	**60%[a]**
CR (3 months)	37%	NR	NR	45%
CR (6 months)	NR	31%	50%	NR
Safety				
CRS	31% grade 1/2; 26% grade 3/4	13% grade ≥3		36% grade 1/2; 0% grade 3/4
Neurotoxicity	13% grade 3/4	28% grade ≥3		4% grade 1/2; 14% grade 3/4

[a]20 pts with DLBCL were evaluated for efficacy.

CR, complete response; CRS, cytokine release syndrome; NR, not reported; ORR, overall response rate.

1. Schuster, SJ, et al. ICML 2017 [abstract 007]. 2. Locke FL, et al. AACR 2017 [abstract CT019]; 3. Locke FL, et al. ASCO 2017 [abstract 7512]; 4. Abramson JS, et al. *Blood*. 2016;128(22) [abstract 4192]; 5. Abramson JS, et al. ASCO 2017 [abstract 7513].

ACCC Association of Community Cancer Centers

sitc Society for Immunotherapy of Cancer

ADVANCES IN Cancer IMMUNOTHERAPY™

Antigen-specific approaches in ALL

Technology:	CAR T cells	BiTE
Example	tisagenlecleucel (CAR(CD19) T)	blinatumumab (anti-CD3/CD19)
Dosing	One infusion	Continuous 28 days
Complete Response	90%	66%
Survival	78% 6 mos OS	9 mos median
Major toxicity	Cytokine release	Cytokine release
Antigen loss relapse?	Yes	Yes
Challenges	Complex manufacturing, individualized	Burdensome infusion

Gill Immunol Rev Dec 2014

ACCC Association of Community Cancer Centers

sitc Society for Immunotherapy of Cancer

ADVANCES IN Cancer IMMUNOTHERAPY™

Patient selection criteria for CAR T therapies

- Expression of the desired antigen for CAR T therapy
  - e.g. CD19 or CD22 expression
- Disease burden
  - CAR T trials: <30% to minimize the risk of cytokine release syndrome
- Presence of co-morbidities
  - e.g. Presence of active autoimmune diseases which could be worsened

ACCC Association of Community Cancer Centers

sitc Society for Immunotherapy of Cancer

Ongoing trials with CAR T therapies for hematologic malignancies

- CD22+ CAR T cells effective in patients with relapsed, CD19- B-ALL





Fry, T.J. et al., Nature Medicine, 2017

Immunotherapies for myeloma

- No approved checkpoint inhibitor therapies
  - KEYNOTE-183/185/023: halted or discontinued due to risk/benefit profile

- Vaccine-based approaches



  - Non-Antigen Specific
    - Attenuated measles
    - Whole cell - GM-CSF
    - Dendritic – tumor fusions
  - Antigen Specific
    - Idiotype: RNA, DNA, protein
    - Pulsed dendritic cells
    - Tumor-specific peptides

ADVANCES IN Cancer IMMUNOTHERAPY™

On the way: BCMA+ CAR T therapy for myeloma



- Fan et al. LBA3001 ASCO 2017

- 100% ORR

- 33/35 patients in remission within 2 months after BCMA CAR T therapy

- November 17th, 2017 FDA Breakthrough Designation

Syed Abbas Ali et al. Blood 2016;128:1688-1700

ACCC Association of Community Cancer Centers

sitc Society for Immunotherapy of Cancer

ADVANCES IN Cancer IMMUNOTHERAPY™

Evolution of Immuno-oncology



ADVANCES IN Cancer IMMUNOTHERAPY™

Further resources

Boyiadzis *et al. Journal for ImmunoTherapy of Cancer* (2016) 4:90
DOI 10.1186/s40425-016-0188-z

Journal for ImmunoTherapy of Cancer

POSITION ARTICLE AND GUIDELINES **Open Access**

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

Michael Boyiadzis[1†], Michael R. Bishop[2†], Rafat Abonour[3], Kenneth C. Anderson[4], Stephen M. Ansell[5], David Avigan[6], Lisa Barbarotta[7], Austin John Barrett[8], Koen Van Besien[9], P. Leif Bergsagel[10], Ivan Borrello[11], Joshua Brody[12], Jill Brufsky[13], Mitchell Cairo[14], Ajai Chari[12], Adam Cohen[15], Jorge Cortes[16], Stephen J. Forman[17], Jonathan W. Friedberg[18], Ephraim J. Fuchs[19], Steven D. Gore[20], Sundar Jagannath[12], Brad S. Kahl[21], Justin Kline[22], James N. Kochenderfer[23], Larry W. Kwak[24], Ronald Levy[25], Marcos de Lima[26], Mark R. Litzow[27], Anuj Mahindra[28], Jeffrey Miller[29], Nikhil C. Munshi[30], Robert Z. Orlowski[31], John M. Pagel[32], David L. Porter[33], Stephen J. Russell[5], Karl Schwartz[34], Margaret A. Shipp[35], David Siegel[36], Richard M. Stone[4], Martin S. Tallman[37], John M. Timmerman[38], Frits Van Rhee[39], Edmund K. Waller[40], Ann Welsh[41], Michael Werner[42], Peter H. Wiernik[43] and Madhav V. Dhodapkar[44*]